An interventional study of INSTI® Rapid Blood Type Test and TruPlex Rapid Blood Type Test in ABO Blood Type and RhD Blood Type, sponsored by bioLytical Laboratories. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by bioLytical Laboratories · Not applicable, Interventional, and Screening
CLS-019A is a prospective, multi-site, parallel clinical performance study. Each enrolled subject is tested on both investigational devices in parallel within a single study visit, yielding paired INSTI® and TruPlex results from matched capillary fingerstick and EDTA-VWB samples.
bioLytical Laboratories is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be enrolled in the Main Cohort if they meet all of criteria IC.1 through IC.6. Subjects will be enrolled in the Rare-Phenotype Cohort if they meet all of criteria IC.1 through IC.7:
Subjects is willing to provide:
Additional Inclusion Criterion for Rare-Phenotype Cohort Enrollment:
Exclusion Criteria:
Subjects will be excluded from the study if they meet any of the following criteria:
Subject has any condition which, in the opinion of the Investigator or Operator, would:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospectively recruited subjects will undergo testing for ABO and RhD blood type using the INSTI and TruPlex Rapid Blood Typing Tests.
Diagnostic Test: INSTI® Rapid Blood Type Test · Diagnostic Test: TruPlex Rapid Blood Type Test
Subjects with rare blood phenotypes will undergo testing for ABO and RhD blood type using the INSTI and TruPlex Rapid Blood Typing Tests.
Diagnostic Test: INSTI® Rapid Blood Type Test · Diagnostic Test: TruPlex Rapid Blood Type Test
A flow-through blood grouping reagent device intended for the determination of ABO and RhD blood group by forward typing using human whole blood samples.
A lateral-flow blood grouping reagent device intended for the determination of ABO and RhD blood group by forward typing using human whole blood samples.
Clinical performance of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood type detection
To evaluate the clinical performance (PPA and NPA) of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood types through detection of A, B, and RhD antigens using both capillary fingerstick and EDTA venous whole blood (VWB) samples. Performance will be determined by comparing the results of each investigational device with reference tests for ABO and RhD status.
Time frame: 6 months
INSTI® and TruPlex Rapid Blood Typing Test Invalid Rate
To monitor and report the rate of invalid test results for the INSTI® and TruPlex Rapid Blood Typing Tests.
Time frame: 6 months
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Nov 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.